Biblio Discovery — Demo Discovery Service

16 results for "Issaka Sagara"

Showing 1–16 · 1.43 seconds · RSS

  1. Journal Article Full text

    Optimal mode for delivery of seasonal malaria chemoprevention in Ouelessebougou, Mali: A cluster randomized trial

    Amadou Barry; Djibrilla Issiaka; Tiangoua Traore et al.

    PLOS ONE, Vol. 13 No. 3 · 2018 · English · PLOS Scopus

    Background: Seasonal malaria chemoprevention (SMC), the administration of complete therapeutic courses of antimalarials to children aged 3–59 months during the malaria transmission season, is a new strategy recommended by the World Health Organization (WHO) for malaria control in Sahelian countries…

  2. Journal Article Full text

    Population impact of malaria control interventions in the health district of Kati, Mali

    Abdoulaye Katile; Issaka Sagara; Mady Cissoko et al.

    PLOS ONE, Vol. 19 No. 12 · 2024 · English · PLOS Scopus

    Background: WHO and its partners have adopted alternative control interventions since the failure to eradicate malaria worldwide in the 1960s and 1970s. The aim of these interventions has been to redesign the control interventions to make them more effective and more efficient. The purpose of this…

  3. Journal Article Full text

    Impact of seasonal malaria chemoprevention timing on clinical malaria incidence dynamics in the Kedougou region, Senegal

    Betty Kazanga; El-Hadj Ba; Eva Legendre et al.

    PLOS Global Public Health, Vol. 5 No. 1 · 2025 · English · PLOS Scopus

    Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine is recommended by the World Health Organization since 2012 for clinical malaria prevention in children in the Sahelian region of Africa. In Senegal, SMC implementation began in 2013 and is given to children under…

  4. Journal Article Full text

    Non-Apical Membrane Antigen 1 (AMA1) IgGs from Malian Children Interfere with Functional Activity of AMA1 IgGs as Judged by Growth Inhibition Assay

    Kazutoyo Miura; Suwani Perera; Sarah Brockley et al.

    PLoS ONE, Vol. 6 No. 6 · 2011 · English · PLOS Scopus

    Background: Apical membrane antigen 1 (AMA1) is one of the best-studied blood-stage malaria vaccine candidates. When an AMA1 vaccine was tested in a malaria naïve population, it induced functionally active antibodies judged by Growth Inhibition Assay (GIA). However, the same vaccine failed to…

  5. Journal Article Full text

    Marked Rise in the Prevalence of Asymptomatic Plasmodium falciparum Infection in Rural Gabon

    Irène Pegha Moukandja; Jean Claude Biteghe Bi Essone; Issaka Sagara et al.

    PLOS ONE, Vol. 11 No. 5 · 2016 · English · PLOS Scopus

    Control strategies implemented a decade ago led to a marked reduction in the prevalence of malaria in many countries. In Dienga, southeastern Gabon, the prevalence of microscopic P. falciparum infection was 7% in 2003, close to the pre-elimination threshold of 5%. The aim of this work was to…

  6. Journal Article Full text

    Geo-epidemiological risk stratification to select malaria interventions, case of Mali

    Mady Cissoko; Mahamadou Magassa; Ibrahim A. Cissé et al.

    PLOS Global Public Health, Vol. 5 No. 11 · 2025 · English · PLOS Scopus

    Malaria is a public health threat in Mali, with high morbidity (37%) and mortality (25%) rates. Malaria risk stratification is needed to identify different risk transmission and select interventions, especially in resource-limited contexts. For the new National Strategic Plan, we updated…

  7. Journal Article Full text

    Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali

    Matthew E. Cairns; Issaka Sagara; Issaka Zongo et al.

    PLOS Medicine, Vol. 17 No. 8 · 2020 · English · PLOS Scopus

    Background: Seasonal malaria chemoprevention (SMC) is now widely deployed in the Sahel, including several countries that are major contributors to the global burden of malaria. Consequently, it is important to understand whether SMC continues to provide a high level of protection and how SMC might…

  8. Journal Article Full text

    Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali

    Hamma Maiga; Estrella Lasry; Modibo Diarra et al.

    PLOS ONE, Vol. 11 No. 9 · 2016 · English · PLOS Scopus

    Background: Seasonal malaria chemoprevention (SMC) with sulphadoxine-pyrimethamine (SP) plus amodiaquine (AQ) is being scaled up in Sahelian countries of West Africa. However, the potential development of Plasmodium falciparum resistance to the respective component drugs is a major concern…

  9. Journal Article Full text

    Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries

    Matthew Cairns; Serign Jawo Ceesay; Issaka Sagara et al.

    PLOS Medicine, Vol. 18 No. 9 · 2021 · English · PLOS Scopus

    Background: Seasonal malaria chemoprevention (SMC) has shown high protective efficacy against clinical malaria and severe malaria in a series of clinical trials. We evaluated the effectiveness of SMC treatments against clinical malaria when delivered at scale through national malaria control…

  10. Journal Article Full text

    Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial

    Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly et al.

    PLoS Clinical Trials, Vol. 1 No. 7 · 2006 · English · PLOS

    Objectives: The objectives were to evaluate the safety, reactogenicity, and allele-specific immunogenicity of the blood-stage malaria vaccine FMP1/AS02A in adults exposed to seasonal malaria and the impact of natural infection on vaccine-induced antibody levels. Design: We conducted a randomized…

  11. Journal Article Full text

    Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian Children

    Alassane Dicko; Issaka Sagara; Ruth D. Ellis et al.

    PLoS ONE, Vol. 3 No. 2 · 2008 · English · PLOS Scopus

    Background: Apical Membrane Antigen-1 (AMA1) is one of the leading blood stage malaria vaccine candidates. AMA1-C1/Alhydrogel® consists of an equal mixture of recombinant AMA1 from FVO and 3D7 clones of P. falciparum, adsorbed onto Alhydrogel®. A Phase 1 study in semi-immune adults in Mali showed…

  12. Journal Article Full text

    Immunological characterization of a VIR protein family member (VIR-14) in Plasmodium vivax -infected subjects from different epidemiological regions in Africa and South America

    Raianna F. Fantin; Camila H. Coelho; Anne D. Berhe et al.

    PLOS Neglected Tropical Diseases, Vol. 17 No. 4 · 2023 · English · PLOS Scopus

    Plasmodium vivax is a major challenge for malaria control due to its wide geographic distribution, high frequency of submicroscopic infections, and ability to induce relapses due to the latent forms present in the liver (hypnozoites). Deepening our knowledge of parasite biology and its molecular…

  13. Journal Article Full text

    Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians

    Alassane Dicko; David J. Diemert; Issaka Sagara et al.

    PLoS ONE, Vol. 2 No. 10 · 2007 · English · PLOS Scopus

    Background: Apical Membrane Antigen 1 (AMA1) of Plasmodium falciparum merozoites is a leading blood-stage malaria vaccine candidate. Protection of Aotus monkeys after vaccination with AMA1 correlates with antibody responses. Study Design/Results: A randomized, controlled, double-blind phase 1…

  14. Journal Article Full text

    Distribution and determinants of COVID-19 seroprevalence in a hard-to-access health district in Mali

    Sekou Oumarou Thera; Mady Cissoko; Jordi Landier et al.

    PLOS Global Public Health, Vol. 5 No. 7 · 2025 · English · PLOS Scopus

    In November 2023, three years after the onset of the pandemic, Mali officially recorded 33,160 confirmed COVID-19 cases and 743 related deaths. Tombouctou health district, following Bamako, the capital city, emerged as the second major hotspot with over 532 confirmed cases. However, these figures…

  15. Journal Article Full text

    Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial

    Mahamadou A. Thera; Ogobara K. Doumbo; Drissa Coulibaly et al.

    PLoS ONE, Vol. 3 No. 1 · 2008 · English · PLOS Scopus

    Background: The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria. Methodology/Principal Findings: A phase 1 double blind randomized controlled dose escalation trial was conducted…

  16. Journal Article Full text

    Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial

    Mahamadou A. Thera; Ogobara K. Doumbo; Drissa Coulibaly et al.

    PLoS ONE, Vol. 5 No. 2 · 2010 · English · PLOS Scopus

    Background: The objective was to evaluate the safety and immunogenicity of the AMA1-based malaria vaccine FMP2.1/AS02A in children exposed to seasonal falciparum malaria. Methodology/Principal Findings: A Phase 1 double blind randomized controlled dose escalation trial was conducted in Bandiagara…